Türkay Cansel, Soykan Irfan, Kir Metin, Ozden Ali
Ankara University Medical School, Department of Gastroenterology.
Turk J Gastroenterol. 2002 Sep;13(3):146-53.
BACKGROUND/AIMS: This study was undertaken to evaluate the effect of eradication therapy on the symptoms of Helicobacter pylori positive non-ulcer dyspepsia patients.
Twenty-four patients participated in the study and the symptoms of daytime epigastric pain, night or hunger pain, nausea, vomiting, regurgitation, bloating, belching, early satiety and anorexia were scored at the beginning, the 15th day after starting eradication therapy (amoxicillin 2 gr bid, clarithromycin 2 gr bid and omeprazole 40 mg daily for two weeks) and during the third and sixth months. Gastric emptying of radiolabelled solid meal was determined at baseline and during the third month.
The Helicobacter pylori eradication rate was 79% and symptom scores significantly decreased during the follow-up period in both of the groups, irrespective of Helicobacter pylori status. The mean symptom scores of the 24 patients at baseline, day 15 and and months three and six were as follows: 1.275, 0.274, 0.496 and 0.238 respectively. Symptom scores for the 19 patients with Helicobacter pylori eradication were 1.084, 0.263, 0.347 and 0.215 respectively while in the five patients in whom Helicobacter pylori eradication therapy failed it was 2.0, 0.314, 1.06 and 0.32 respectively. Of the 16.6% Helicobacter pylori positive non-ulcer dyspepsia patients who had delayed gastric emptying of solids, there was no change after eradication therapy. Nine patients, including all of those in whom eradication therapy failed, required further medication (antacids/prokinetics) for continuing symptoms one month after completion of treatment.
The results of this study suggest that Helicobacter pylori is a causal factor in symptoms of non-ulcer dyspepsia and that eradication therapy improves symptoms and endoscopic findings but has no effect on gastric emptying.
背景/目的:本研究旨在评估根除疗法对幽门螺杆菌阳性的非溃疡性消化不良患者症状的影响。
24名患者参与了本研究,在开始时、开始根除疗法(阿莫西林2克,每日两次;克拉霉素2克,每日两次;奥美拉唑40毫克,每日一次,持续两周)后的第15天以及第三个月和第六个月时,对日间上腹部疼痛、夜间或饥饿痛、恶心、呕吐、反流、腹胀、嗳气、早饱及厌食等症状进行评分。在基线期和第三个月时测定放射性标记固体餐的胃排空情况。
幽门螺杆菌根除率为79%,两组患者在随访期间症状评分均显著降低,与幽门螺杆菌状态无关。24名患者在基线期、第15天、第三个月和第六个月时的平均症状评分分别如下:1.275、0.274、0.496和0.238。19名幽门螺杆菌被根除患者的症状评分分别为1.084、0.263、0.347和0.215,而5名根除疗法失败患者的症状评分分别为2.0、0.314、1.06和0.32。在16.6%的幽门螺杆菌阳性非溃疡性消化不良且固体胃排空延迟的患者中,根除疗法后无变化。9名患者,包括所有根除疗法失败的患者,在完成治疗1个月后因症状持续需要进一步用药(抗酸剂/促动力药)。
本研究结果表明,幽门螺杆菌是非溃疡性消化不良症状的一个致病因素,根除疗法可改善症状和内镜检查结果,但对胃排空无影响。